Fabiola N. Velazquez

Fabiola N. Velazquez

Auto-generated profile, based on publicly available information

Fabiola N. Velazquez

Department of Medicine, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2023 in The FASEB Journal
Verified
Journal Article
Closed access
FVFabiola N. Velazquez
Fabiola N. Velazquez
JSJeffrey L. Stith
Jeffrey L. Stith
LZLeiqing Zhang
Leiqing Zhang
AAAmira M. Allam
Amira M. Allam
JHJohn A. Haley
John A. Haley
YHYusuf Hannun
Yusuf Hannun

27 May 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
FVFabiola N. Velazquez
Fabiola N. Velazquez
LZLeiqing Zhang
Leiqing Zhang
VVValentina Viscardi
Valentina Viscardi
CTCarolena Trocchia
Carolena Trocchia
YHYusuf A. Hannun
Yusuf A. Hannun
Ashley J SniderAshley J Snider
Ashley J Snider
Breast cancer is a very heterogeneous disease, and ~30% of breast cancer patients succumb to metastasis, highlighting the need to understand the mechanisms of breast cancer progression in order to identify new molecular targets for treatment. Sphingosine kinase 1 (SK1) has been shown to be upregulated in patients with breast cancer, and several studies have suggested its involvement in breast cancer progression and/or metastasis, mostly based on cell studies. In this work we evaluated the role of SK1 in breast cancer development and metastasis using a transgenic breast cancer model, mouse mammary tumor virus-polyoma middle tumor-antigen (MMTV-PyMT), that closely resembles the characteristics and evolution of human breast cancer. The results show that SK1 deficiency does not alter tumor latency or growth, but significantly increases the number of metastatic lung nodules and the average metastasis size in the lung of MMTV-PyMT mice. Additionally, analysis of Kaplan-Meier plotter of human disease shows that high SK1 mRNA expression can be associated with a better prognosis for breast cancer patients. These results suggest a metastasis-suppressing function for SK1 in the MMTV-PyMT model of breast cancer, and that its role in regulating human breast cancer progression and metastasis may be dependent on the breast cancer type.

18 October 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
SSSuchandrima Saha
Suchandrima Saha
FVFabiola N. Velazquez
Fabiola N. Velazquez
FDFatemeh Dehpanah
Fatemeh Dehpanah
BBBrianna L. Bergfalk
Brianna L. Bergfalk
SMSamantha Mulkeen
Samantha Mulkeen
DMDavid C Montrose
David C Montrose
Deoxysphingolipids (deoxySLs) are a class of non-canonical sphingolipids that can adversely impact mitochondrial function. Mitochondrial disruption can activate the cyclic GMP–AMP synthase–stimulator of interferon genes (cGAS–STING1) pathway, and in turn, promote antitumor immunity. Here, we investigated whether inducing deoxySL accumulation in colon cancer cells drives immune-specific, antitumor effects. We show that depleting serine increased deoxySLs and enhanced immune cell infiltration in colon tumors, in parallel with suppressing tumor growth. Elevating tumor deoxySL levels through mutation of SPT in cells and feeding a high alanine diet to mice exerted similar effects, including immune-mediated tumor growth suppression. Work conducted in multiple in vitro systems identified deoxySLs as key triggers of cGAS-STING1 activation, an effect mediated by mitochondrial release of double-stranded DNA resulting from mitochondrial stress. Collectively, these findings provide the first evidence that deoxySLs can drive antitumor immunity and identify a previously unrecognized metabolic strategy for cancer therapy.

2 September 2026 in Journal of Lipid Research
Verified
Journal Article
Open access
FVFabiola N. Velazquez
Fabiola N. Velazquez
KLKarissa J. Lopez
Karissa J. Lopez
BKBahman Khalvatifahlylani
Bahman Khalvatifahlylani
DCDaniel Canals
Daniel Canals
YHYusuf Hannun
Yusuf Hannun